1 specialty the exception as telehealth continues to tumble

Going by private health-insurance data, national telehealth utilization dropped 12.5% this spring, slipping from 5.6% of claims in March to 4.9% in April.

This made for a three-month trend as recorded by Fair Health’s monthly regional telehealth tracker. The service showed declines of 5.1% in March vs. February and of 15.7% in February vs. January.

The falloff owes largely to the comeback of in-person doctor visits following telemedicine’s surge during the public health crisis brought on by COVID, Fair Health points out in a July 7 news release.

One corner of U.S. healthcare is bucking the trend: Virtual mental healthcare is still on the rise, growing from 57% of claims in March to 58.6% in April.

Also of interest, acute respiratory ailments increased in April as a percentage of telehealth claim lines nationally and in the Midwest and South.

“As the COVID-19 pandemic wanes, this suggests a return to non-COVID respiratory conditions, such as colds and bronchitis,” the nonprofit consumer group says.

“Also in April,” Fair Health notes, “general signs and symptoms joined the top five telehealth diagnoses in the West, again suggesting a return to more ‘ordinary,’ non-COVID conditions such as colds and stomach viruses.”

The findings are consistent with those from Trilliant, which recently reported U.S. telehealth sessions falling below 10 million in January for the first time since the spring of 2020.

Fair Health news release here, latest interactive tracking map here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.